Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403
      QxMD      Google Scholar   
Citation:
Am. J. Hematol. vol 95 (6) 583-593
Year:
2020
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
9
Parents:
683   978   2033   2392   2705   2994  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
Millennium  
Grants:
U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233327, UG1CA233331, UG1CA233339  
Corr. Author:
 
Authors:
                                   
Networks:
11030, CA824, CAPITAL, COLUMBUS, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY158, LAPS-OH007, NC002, NY018, OH070   
Study
CALGB-50403
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Mantle Cell Lymphoma, Marrow/Stem Cell Transplant, clinical, Clinical Trials, bortezomib, maintenance therapy